Your browser doesn't support javascript.
loading
Recent advances with erythrocytes as therapeutics carriers.
Hadi Barhaghtalab, Reyhaneh; Tanimowo Aiyelabegan, Hammed; Maleki, Hassan; Mirzavi, Farshad; Gholizadeh Navashenaq, Jamshid; Abdi, Fereshteh; Ghaffari, Faezeh; Vakili-Ghartavol, Roghayyeh.
Afiliación
  • Hadi Barhaghtalab R; Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Tanimowo Aiyelabegan H; Department of Biochemistry, Kwara State University, Malete, Nigeria.
  • Maleki H; Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Mirzavi F; Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
  • Gholizadeh Navashenaq J; Noncommunicable Diseases Research Center, Bam University of Medical Sciences, Bam, Iran.
  • Abdi F; Department of Medical Nanotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran; Noncommunicable Diseases Research Center, Bam University of Medical Sciences, Bam, Iran.
  • Ghaffari F; Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Medical Nanotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Vakili-Ghartavol R; Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Medical Nanotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: Roghayyehvakili@sums.ac.ir.
Int J Pharm ; 665: 124658, 2024 Sep 03.
Article en En | MEDLINE | ID: mdl-39236775
ABSTRACT
Erythrocytes have gained popularity as a natural option for in vivo drug delivery due to their advantages, which include lengthy circulation times, biocompatibility, and biodegradability. Consequently, the drug's pharmacokinetics and pharmacodynamics in red blood cells can be considerably up the dosage. Here, we provide an overview of the erythrocyte membrane's structure and discuss the characteristics of erythrocytes that influence their suitability as carrier systems. We also cover current developments in the erythrocyte-based nanocarrier, which could be used for both active and passive targeting of disease tissues, particularly those of the reticuloendothelial system (RES) and cancer tissues. We also go over the most recent discoveries about the in vivo and in vitro uses of erythrocytes for medicinal and diagnostic purposes. Moreover, the clinical relevance of erythrocytes is discussed in order to improve comprehension and enable the potential use of erythrocyte carriers in the management of various disorders.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Pharm Año: 2024 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Pharm Año: 2024 Tipo del documento: Article País de afiliación: Irán
...